Arkolith/Insider Trading/AVTX/Form 4

Sullivan Christopher Ryan

Chief Financial OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Jun 12, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 10, 2026Tax withholding(F)138$13.10$2K41K

Transaction Codes

F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001810417-26-000016) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML